ERBB2 and breast carcinoma: Olaparib, a polyadenosine 5’diphosphoribose polymerase (PARP) inhibitor, resulted in an absolute invasive disease-free survival (IDFS) benefit of 8.8% at 3 years for patients with early-stage, high-risk, germline BRCA-mutated, HER2 negative breast cancer.